Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?

Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?

Breast cancer is the most common malignant disease in the world. One of the methods of treating breast cancer is neoadjuvant chemotherapy. Neoadjuvant chemotherapy (NCT) is now the standard of care for locally advanced breast cancer. Patients with HER2-positive and triple-negative breast cancer subt...

Full description

Bibliographic Details
Main Authors:	V. V. Vorotnikov, R. A. Pakhomova, A. V. Soinov, A. S. Gunina, I. V. Kopytich, M. G. Tsoi, S. A. Abdugafforov
Format:	Article
Language:	English
Published:	Bashkir State Medical University 2022-10-01
Series:	Креативная хирургия и онкология
Subjects:	рак молочной железы неоадъювантная химиотерапия неоадъювантная гормонотерапия тройное негативное новообразование молочной железы профилирование генной экспрессии тамоксифен летрозол таселисиб палбоциклиб
Online Access:	https://www.surgonco.ru/jour/article/view/714

Similar Items

Femara (letrozol) v sovremennoy terapii raka molochnoy zhelezy
by: N I Perevodchikova
Published: (2008-06-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
by: Yu. S. Sidorenko, et al.
Published: (2014-08-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

PREDICTIVE VALUE OF MOLECULAR PARAMETERS IN PATIENTS WITH BASAL-LIKE TRIPL-NEGATIVE BREAST CANCER
by: О. D. Bragina, et al.
Published: (2016-02-01)

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01)

Correlation of the value of sonoelastography strain ratio with the degree of pathological regression in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
by: E. A. Bus’ko, et al.
Published: (2017-02-01)

Aberrations of the number of copies (CNA) in the genome of luminal B breast tumor
by: M. K. Ibragimova, et al.
Published: (2020-10-01)

IMMEDIATE RESPONSE TO NEOADJUVANT CHEMOTHERAPY INCLUDING CAPECITABINE AND LONG-TERM TREATMENT OUTCOMES OF OPERABLE BREAST CANCER
by: E. M. Slonimskaya, et al.
Published: (2016-07-01)

Ten-year adjuvant hormone therapy for breast cancer: the pros and cons (a review of literature)
by: S. M. Portnoy, et al.
Published: (2014-07-01)

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS
by: Y. V. Kukharev, et al.
Published: (2016-02-01)

Time course of changes in 6-sulfatoxymelatonin excretion in patients with breast cancer after various neoadjuvant chemotherapy options
by: Yu. S. Sidorenko, et al.
Published: (2014-07-01)

Metformin in the treatment of breast cancer among patients with metabolic syndrome
by: R. V. Lyubota
Published: (2015-11-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Magnetic resonance imaging in evaluation of efficiency of neoadjuvant chemotherapy of breast cancer
by: A. V. Komyahov, et al.
Published: (2015-12-01)

HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE
by: L. Yu. Vladimirova, et al.
Published: (2020-06-01)

Role of positron emission tomography in predicting early tumor response to neoadjuvant chemotherapy for breast cancer
by: N. G. Chanchikova, et al.
Published: (2021-01-01)

Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression
by: N. V. Litviakov
Published: (2016-02-01)

BRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancer
by: M. M. Tsyganov, et al.
Published: (2018-05-01)

Gene expression analysis of ABC transporter family in breast tumors: relationship with chemotherapy effect and disease prognosis
by: M. M. Tsyganov, et al.
Published: (2020-09-01)

MICROARRAY ANALYSIS OF DNA COPY NUMBER ABERRATION IN BREAST TUMOR: CORRELATION WITH THE EFFICACY OF NEOADJUVANT CHEMOTHERAPY
by: N. V. Litviakov, et al.
Published: (2016-02-01)

Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
by: V F Semiglazov, et al.
Published: (2009-09-01)

Long-term results of complete clinical and pathologic regression in patients with breast cancer
by: S. M. Demidov, et al.
Published: (2016-09-01)

COMPARATIVE ANALYSIS OF THE CONTENT IN LYMPH OF HORMONES DRAWING IN PATHOGENESIS OF BREAST CANCER IN RATS WISTAR
by: A. P. Lykov, et al.
Published: (2016-02-01)

Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014-07-01)

HETEROGENENOUS EXPRESSION OF MARKERS ASSOCIATED WITN INVASIVE BREAST CANCER
by: N. V. Krakhmal, et al.
Published: (2016-10-01)

A PARADIGM SHIFT IN THE TREATMENT OF PATIENTS WITH RESECTABLE PANCREATIC CANCER
by: E. Yu. Antonova, et al.
Published: (2020-07-01)

Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review)
by: D. N. Kravchenko, et al.
Published: (2018-10-01)

PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF KI67 DYNAMIC CHANGE DURING PREOPERATIVE ENDOCRINE THERAPY IN BREAST CNACER PATIENTS
by: M. V. Rodionova, et al.
Published: (2016-02-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
by: M. K. Ibragimova, et al.
Published: (2022-03-01)

BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
by: A. R. Bosieva, et al.
Published: (2021-08-01)

CYP2D6-GENOTYPING IN THE ASSESSMENT OF THE EFFECTIVENESS OF THERAPY WITH TAMOXIFEN IN PATIENTS WITH ADVANCED HORMONE RECEPTOR-POSITIVE BREAST CANCER
by: L. N. Lyubchenko, et al.
Published: (2017-12-01)

MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS
by: P. V. Kazantseva, et al.
Published: (2016-07-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020-11-01)

Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer
by: L. N. Lyubchenko, et al.
Published: (2017-10-01)

The endometrium in women receiving adjuvant tamoxifen therapy after surgical treatment of breast cance
by: E V Dmitrieva, et al.
Published: (2013-12-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

News on preoperative chemotherapy for breast cancer: according to the proceedings of the 33rd Annual Breast Cancer Symposium (December 8–12, 2010, San-Antonio, USA)
by: S. M. Portnoy
Published: (2014-07-01)

CHANGES IN DNA METHYLATION PROFILE IN TAMOXIFEN-RESISTANT MCF-7 SUBLINES
by: О. Е. Andreeva, et al.
Published: (2019-11-01)